KYVERNA THERAPEUTICS, INC.

Andere talen Kyverna Therapeutics, Inc.

Aandelen

KYTX

US5019761049

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 17-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
15,41 ^USD	+1,03%		+10,05%	0,00%

14/05	Kyverna Therapeutics Q1 Verlies vermindert	MT
25/04	Inkomsten Nasdaq beter door sterke vraag naar fintech-producten	RE

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Kyverna Therapeutics Q1 Loss Narrows	14/05
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results	14/05
Nasdaq's revenue beats on strong demand for fintech products	25/04
First-in-Disease Use of Kyverna Therapeutics KYV-101 in Patients with Progressive Multiple sclerosis Published in Med1	01/04
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med	29/03
Kyverna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results	26/03
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to S&P TMI Index	18/03
Sector Update: Health Care Stocks Steady Pre-Bell Friday	08/03
Kyverna Therapeutics Teams Up With Stanford University to Evaluate Investigational Multiple Sclerosis Drug	08/03
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis	08/03
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis	08/03
Kyverna Therapeutics Closes $366.9 Million Initial Public Offering	13/02
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares	12/02
Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut	09/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Ontdek onze gratis inhoud om de beurs beter te leren begrijpen.

Gratis inschrijven

fermer